Rapamycin for longevity: opinion article | Zendy

Mikhail V. Blagosklonny | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapamycin for longevity: opinion article

Author(s) -

Mikhail V. Blagosklonny

Publication year - 2019

Publication title -

aging

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.473

H-Index - 90

ISSN - 1945-4589

DOI - 10.18632/aging.102355

Subject(s) - everolimus , longevity , immortality , pi3k/akt/mtor pathway , life expectancy , blindness , medicine , intensive care medicine , pharmacology , gerontology , biology , literature , art , apoptosis , biochemistry , population , environmental health , optometry

From the dawn of civilization, humanity has dreamed of immortality. So why didn't the discovery of the anti-aging properties of mTOR inhibitors change the world forever? I will discuss several reasons, including fear of the actual and fictional side effects of rapamycin, everolimus and other clinically-approved drugs, arguing that no real side effects preclude their use as anti-aging drugs today. Furthermore, the alternative to the reversible (and avoidable) side effects of rapamycin/everolimus are the irreversible (and inevitable) effects of aging: cancer, stroke, infarction, blindness and premature death. I will also discuss why it is more dangerous not to use anti-aging drugs than to use them and how rapamycin-based drug combinations have already been implemented for potential life extension in humans. If you read this article from the very beginning to its end, you may realize that the time is now.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research